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Drugs or 
Medicines?
Drugs – Dangerous, illegal 
substances that are abused 
Medicines – Legal substances 
that are safe and helpful  
Psychedelics – Illegal substances 




Psilocybin – Magic 
mushrooms, Shrooms 
LSD – Acid 
DMT – Ayahuasca 
Ketamine – horse 
anesthetic 
Classification and Scheduling
o Scheduling results in the substances’ legality
o Schedule 1 substances – High risk of abuse, and no medical 
purposes
o Higher schedule number means the substance is at a lower risk of 




1971 convention of psychotropic 
substances 
Psychedelics were deemed illegal and 
useless before science understood them 
An outdated system
Potentially biased system 
Psychedelics as 
Medicine
Carhart-Harris et al. Psilocybin Study 
◦ Psilocybin improved memory recollection 
◦ fMRI showed stronger activation in visual and 




◦ Extreme openness to intense emotions 
◦ Releases repressed feelings 
◦ Helps patients talk about, and recognize 
painful experiences
◦ Overall enhanced emotional processing 
Antagonist 
Vs. Agonist 
Antagonistic Drugs – Bind to the 
targeted site, trigger no reaction, 
and prohibit other neurotransmitters 
from binding to the receptor site.
Agonistic Drugs – Bind to the 




Serotonin 5HT2A Receptor 
Credited with mood 
and emotional 
regulation
Most antianxiety and 
antidepressants involve 
the 5HT2A receptor site
• Act as antagonists  
Psychedelics bind to 
same receptor site




§Orsolini et al. studied the 
effects of DMT via 
ayahuasca 
§Dimethyltryptamine   
(DMT) – active psychedelic 
chemical in ayahuasca
§Ayahuasca is a kind of tea 
brewed from a vine 
indigenous to the Amazon 




oPsilocybin, DMT, and Ketamine
oLower the amount of dopamine in the 
brains reward pathways 
o Helps fight against addiction
Single Dose Longevity 
Dos Santos et al. Study
oTerminal patients with anxiety and depression
oLSD and Psilocybin 
oEffects were almost immediate 
oAnxiety levels remained reduced for 3 months after 
experiment 
oDepression levels remained reduced for 6 months after 
experiment 
Psychedelic Therapy 
Professional administration yields best results
Avoids negative experience from substances
Challenge experience 
Belief Relaxation 
Positive reinforcement and Cognitive therapy 
Recap on Psychedelics 
Psilocybin, LSD, and 
DMT, all interact 




Fast acting with 
long lasting effects 





• Psilocybin, DMT, 
MDMA, and Ketamine 
used to treat addiction 
Psychedelics 
Wrapped Up 
Further research is needed
Faster and effects last longer than traditional 
options 
Less addictive than their legal counterparts 
Improve vivid memory recollection, and 
emotional openness 
The full realm of possibilities is unknown 
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